Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials

In the phase III POETYK PSO-1 and PSO-2 trials, deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, was well tolerated and efficacious over 1 year in patients with psoriasis.